Claritas Pharmaceuticals Stock Net Income
| CLAZF Stock | USD 0.0001 0.00 0.00% |
Claritas Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Claritas Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Claritas Pharmaceuticals' valuation are provided below:Claritas Pharmaceuticals does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Claritas |
Claritas Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Claritas Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Claritas Pharmaceuticals.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Claritas Pharmaceuticals on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Claritas Pharmaceuticals or generate 0.0% return on investment in Claritas Pharmaceuticals over 90 days. Claritas Pharmaceuticals is related to or competes with Opthea, Inventiva, SS Innovations, and SupermaxBerhad. Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commerciali... More
Claritas Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Claritas Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Claritas Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
Claritas Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Claritas Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Claritas Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Claritas Pharmaceuticals historical prices to predict the future Claritas Pharmaceuticals' volatility.Claritas Pharmaceuticals Backtested Returns
We have found three technical indicators for Claritas Pharmaceuticals, which you can use to evaluate the volatility of the firm. The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Claritas Pharmaceuticals are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Claritas Pharmaceuticals has perfect predictability. Overlapping area represents the amount of predictability between Claritas Pharmaceuticals time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Claritas Pharmaceuticals price movement. The serial correlation of 1.0 indicates that 100.0% of current Claritas Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Claritas Pharmaceuticals reported net income of 4.21 M. This is 98.77% lower than that of the Healthcare sector and 93.99% lower than that of the Biotechnology industry. The net income for all United States stocks is 99.26% higher than that of the company.
Claritas Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Claritas Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Claritas Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Claritas Pharmaceuticals by comparing valuation metrics of similar companies.Claritas Pharmaceuticals is currently under evaluation in net income category among its peers.
Claritas Fundamentals
| Return On Equity | 0.65 | |||
| Return On Asset | 0.0277 | |||
| Current Valuation | 948.45 K | |||
| Shares Outstanding | 36.59 M | |||
| Shares Owned By Insiders | 0.26 % | |||
| Price To Earning | 0.04 X | |||
| Price To Book | 0.12 X | |||
| EBITDA | (449 K) | |||
| Net Income | 4.21 M | |||
| Cash And Equivalents | 2 K | |||
| Total Debt | 538 K | |||
| Debt To Equity | 0.16 % | |||
| Current Ratio | 1.42 X | |||
| Book Value Per Share | 0.09 X | |||
| Cash Flow From Operations | (309 K) | |||
| Earnings Per Share | 0.15 X | |||
| Beta | 2.25 | |||
| Market Capitalization | 664.66 K | |||
| Total Asset | 10.45 M | |||
| Z Score | 0.6 | |||
| Net Asset | 10.45 M |
About Claritas Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Claritas Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Claritas Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Claritas Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Claritas Pink Sheet
Claritas Pharmaceuticals financial ratios help investors to determine whether Claritas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Claritas with respect to the benefits of owning Claritas Pharmaceuticals security.